SeekingAlpha · Feb 27, 2026
AN
NASDAQ · ANIP
ANI Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$71.52
Down-$1.06 (-1.46%)
Updated Oct 7, 2026, 11:29 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.66B
- P/E ratio
- 18.92
- Dividend yield
- 0.00%
- 52-week range
- $69.58 – $97.00
- Volume
- 292K
- Avg. volume
- 437.34K
Price performance · ANIP
ANIP price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ANIP closed at $71.52 after 21 trading sessions, up 1.84% for the selected period.
- Last close
- $71.52
- Period change
- +1.84%
- Period low
- $70.19
- Period high
- $78.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $72.99 | $72.99 | $70.80 | $71.52 | 292K |
| Oct 5, 2026 | $72.57 | $73.4009 | $71.76 | $72.58 | 346.87K |
| Oct 2, 2026 | $73.16 | $73.27 | $71.73 | $72.18 | 309.51K |
| Oct 1, 2026 | $72.54 | $73.956 | $71.64 | $72.96 | 316.69K |
| Sep 30, 2026 | $73.01 | $73.84 | $72.3657 | $72.65 | 383.96K |
| Sep 29, 2026 | $74.14 | $74.78 | $72.47 | $72.62 | 328.84K |
| Sep 28, 2026 | $73.72 | $74.92 | $73.05 | $74.83 | 421.73K |
| Sep 25, 2026 | $74.00 | $74.97 | $73.30 | $74.00 | 278.68K |
| Sep 24, 2026 | $74.00 | $75.50 | $73.6859 | $74.04 | 368.8K |
| Sep 23, 2026 | $77.00 | $78.855 | $74.21 | $74.43 | 433.65K |
| Sep 22, 2026 | $78.49 | $79.315 | $76.575 | $77.91 | 469.57K |
| Sep 21, 2026 | $75.50 | $79.43 | $75.00 | $78.85 | 579.34K |
| Sep 18, 2026 | $75.88 | $77.41 | $74.205 | $76.14 | 1.16M |
| Sep 17, 2026 | $73.68 | $75.67 | $73.54 | $75.39 | 586.05K |
| Sep 16, 2026 | $72.21 | $73.86 | $72.21 | $73.59 | 431.6K |
| Sep 15, 2026 | $70.89 | $72.24 | $69.995 | $72.11 | 464.35K |
| Sep 14, 2026 | $70.79 | $71.87 | $70.15 | $70.40 | 357.66K |
| Sep 11, 2026 | $71.53 | $71.92 | $69.58 | $70.19 | 371.4K |
| Sep 10, 2026 | $70.52 | $71.48 | $70.07 | $71.46 | 228.89K |
| Sep 9, 2026 | $70.23 | $70.925 | $69.96 | $70.70 | 298.34K |
| Sep 8, 2026 | $70.57 | $71.84 | $70.16 | $70.23 | 253.68K |
Latest ANIP news
The latest Smart Investors Daily articles mentioning ANIP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ANIP research
Overview
Company profile and research snapshot.
Company profile
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $104.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Perform | — |
| Aug 10, 2026 | Guggenheim | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Hold | — |
| Jul 17, 2026 | Canaccord Genuity | Hold | — |
| Jul 10, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Feb 27, 2026
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Surges 12% After Q4 Earnings Beat
ANI Pharmaceuticals' strong Q4 earnings beat estimates, driving shares up 12%. The company also reaffirmed its 2026 guidance above analyst expectations.
SeekingAlpha · Feb 27, 2026
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call February 27, 2026 8:00 AM ESTCompany ParticipantsNikhil Lalwani - President, CEO &...
Benzinga · Feb 27, 2026
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
ANI Pharma beats Q4 estimates, swings to profit, and sees over $1 billion in 2026 sales as Rare Disease revenue surges 50%.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
